发明名称 EphA2 T-cell epitope agonists and uses therefore
摘要 EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.
申请公布号 US9359402(B2) 申请公布日期 2016.06.07
申请号 US201314069208 申请日期 2013.10.31
申请人 UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 发明人 Storkus Walter J.;Kinch Michael S.
分类号 A61K39/00;C12N15/09;A61K38/00;C07K7/06;C07K14/47;C07K14/705;G01N33/50;G01N33/569;A61K38/17;C07K7/08 主分类号 A61K39/00
代理机构 Baker Botts L.L.P. 代理人 Baker Botts L.L.P.
主权项 1. A method of eliciting an immune response to EphA2 in a subject, comprising administering, to the subject, an effective amount of an isolated peptide that consists of 9-35 amino acid residues and wherein said isolated peptide comprises the peptide TLADFDPRV (SEQ ID NO:2, residues 883-891), where said TLADFDPRV (SEQ ID NO:2, residues 883-891) peptide (i) has up to one conservative amino acid substitution within the conservative substitution groups (a) S and T, (b) L, I and V, and (c) E and D; and (ii) retains the ability to stimulate a T-cell immune response to EphA2 as determined by ELISPOT assay.
地址 Pittsburgh PA US